Targovax ASA announced that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO), effective as of 7 March 2022. Most recently, he served as Managing Director and Head of Europe at Locust Walk. Before Locust Walk, he was Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall and Head of Europe Search and Evaluation for oncology at Bristol-Myers Squibb.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 NOK | -1.89% | -8.77% | -63.89% |
May. 29 | Transcript : Circio Holding ASA - Special Call | |
May. 29 | Norway's Circio Sets Terms of NOK52 Million Rights Issue Proposal | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.89% | 2.35M | |
+18.77% | 125B | |
+14.05% | 108B | |
-7.16% | 23.64B | |
+1.83% | 22.39B | |
-12.27% | 17.78B | |
-41.74% | 16.43B | |
-13.47% | 16.34B | |
+2.23% | 13.56B | |
+27.13% | 11.59B |
- Stock Market
- Equities
- TRVX Stock
- News Circio Holding ASA
- Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022